Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Mayer KH, Jones D, Oldenburg C, Jain S, Gelman M, Zaslow S, Grasso C, Mimiaga MJ.

J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):535-539. doi: 10.1097/QAI.0000000000001440.

PMID:
28696345
2.

Pre- and post-sexual exposure prophylaxis of HIV: An update.

Marfatia YS, Jose SK, Baxi RR, Shah RJ.

Indian J Sex Transm Dis. 2017 Jan-Jun;38(1):1-9. doi: 10.4103/ijstd.IJSTD_26_17. Review.

3.

Needlestick and Sharps Injuries in Dermatologic Surgery: A Review of Preventative Techniques and Post-exposure Protocols.

Rizk C, Monroe H, Orengo I, Rosen T.

J Clin Aesthet Dermatol. 2016 Oct;9(10):41-49. Epub 2016 Oct 1. Review.

4.

Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Naggie S, Holland DP, Sulkowski MS, Thomas DL.

Clin Infect Dis. 2017 Jan 1;64(1):92-99. Epub 2016 Sep 28.

PMID:
27682067
5.

Novel immunological strategies for HIV-1 eradication.

Jülg B, Barouch DH.

J Virus Erad. 2015 Oct 1;1(4):232-6. Review.

6.

Prescription of Non-Occupational Post-Exposure HIV Prophylaxis by Emergency Physicians: An Analysis on Accuracy of Prescription and Compliance.

Malinverni S, Libois A, Gennotte AF, La Morté C, Mols P.

PLoS One. 2016 Apr 12;11(4):e0153021. doi: 10.1371/journal.pone.0153021. eCollection 2016.

7.

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Halper-Stromberg A, Nussenzweig MC.

J Clin Invest. 2016 Feb;126(2):415-23. doi: 10.1172/JCI80561. Epub 2016 Jan 11. Review.

8.

Nondaily preexposure prophylaxis for HIV prevention.

Anderson PL, García-Lerma JG, Heneine W.

Curr Opin HIV AIDS. 2016 Jan;11(1):94-101. doi: 10.1097/COH.0000000000000213. Review.

9.

Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men.

Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ.

Open Forum Infect Dis. 2015 Jan 1;2(1):ofu114. doi: 10.1093/ofid/ofu114. eCollection 2015 Jan.

10.

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.

Massud I, Martin A, Dinh C, Mitchell J, Jenkins L, Heneine W, Pau CP, García-Lerma JG.

J Antimicrob Chemother. 2015 May;70(5):1473-81. doi: 10.1093/jac/dku556. Epub 2015 Jan 27.

11.

Universal children's day--let's improve current interventions to reduce vertical transmission of HIV now.

Cotton MF, Rabie H.

J Int AIDS Soc. 2014 Nov 20;17:19875. doi: 10.7448/IAS.17.1.19875. eCollection 2014. No abstract available.

12.

Strategies for preventing mucosal cell-associated HIV transmission.

Whaley KJ, Mayer KH.

J Infect Dis. 2014 Dec 15;210 Suppl 3:S674-80. doi: 10.1093/infdis/jiu398. Review.

13.

Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.

Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Rower C, Klein B, Kerr BJ, Guida LA, Zheng JH, Bushman LR, Anderson PL.

Clin Infect Dis. 2015 Mar 1;60(5):804-10. doi: 10.1093/cid/ciu916. Epub 2014 Nov 18. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

14.

Current perspectives in HIV post-exposure prophylaxis.

Sultan B, Benn P, Waters L.

HIV AIDS (Auckl). 2014 Oct 24;6:147-58. doi: 10.2147/HIV.S46585. eCollection 2014. Review.

15.

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21. doi: 10.1073/pnas.1413550111. Epub 2014 Oct 27. Review.

16.

Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Beekmann SE, Henderson DK.

Infect Dis Clin North Am. 2014 Dec;28(4):601-13. doi: 10.1016/j.idc.2014.08.005. Epub 2014 Oct 5. Review.

17.

Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS Jr, Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis GK, Pazgier M.

J Virol. 2014 Nov;88(21):12895-906. doi: 10.1128/JVI.02194-14. Epub 2014 Aug 27.

18.

Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.

McDougal SJ, Alexander J, Dhanireddy S, Harrington RD, Stekler JD.

PLoS One. 2014 Aug 20;9(8):e105030. doi: 10.1371/journal.pone.0105030. eCollection 2014.

19.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-999. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

20.

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.

Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH.

Nature. 2014 Aug 7;512(7512):74-7. doi: 10.1038/nature13594. Epub 2014 Jul 20.

Supplemental Content

Support Center